

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

| | | |
|---|---|---------------|
| Patient Name: | Prescriber Name: | |
| Member Number: | Fax: | Phone: |
| Date of Birth: | Office Contact: | |
| Line of Business: <input type="checkbox"/> Medicare | NPI: | State Lic ID: |
| Address: | Address: | |
| City, State ZIP: | City, State ZIP: | |
| Primary Phone: | Specialty/facility name (if applicable): | |

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that applying the 72 hour standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

| | |
|-------------------|--|
| Drug Name: | |
| Strength: | |
| Directions / SIG: | |

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

| |
|--|
| <p>Q1. Is this a request for a continuation of therapy with intravenous immune globulin?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q2. Has the patient demonstrated clinical response to therapy based on an objective clinical measuring tool appropriate to the diagnosis (such as INCAT, Medical Research Council (MRC) muscle strength, 6-MWT, Rankin, Modified Rankin, Activities of Daily Living (ADL) scores)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q3. Is the requested product being prescribed by or in consultation with a specialist (allergist, immunologist, hematologist, cardiologist, oncologist, or neurologist)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q4. Is the request for one of the following formulary products: Bivigam, Flebogamma, Gammagard Liquid, Gammagard S/D, Gammplex, Gamunex-C, Octagam, Panzyga, or Privigen?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q5. Is the medication covered under Medicare Part B?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q6. Does the patient have the diagnosis of autoimmune mucocutaneous blistering disease (e.g., pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane [cicatricial] pemphigoid, benign mucous membrane pemphigoid, epidermolysis bullosa acquisita)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

| | |
|----------------------|-------------------------|
| Patient Name: | Prescriber Name: |
|----------------------|-------------------------|

| |
|--|
| <p>Q7. Does the patient meet one of the following: A) inadequate response or inability to tolerate conventional therapy (i.e., steroids, immunosuppressants) OR B) rapidly progressive disease in conjunction with conventional therapy (i.e., steroids, immunosuppressants)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q8. Does a patient have erythema multiforme major (SJS, TEN) and SCORTEN level 3 or greater? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q9. Does the patient have the diagnosis of scleromyxedema? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q10. Does the patient have the diagnosis of acute idiopathic thrombocytopenia purpura (ITP)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q11. Does the patient require or have ONE of the following: A) management of acute bleeding, B) need to increase platelet count prior to surgical procedures, C) severe thrombocytopenia (platelets less than 20,000 per microliter), or D) high risk for intracerebral hemorrhage? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q12. Does the patient have the diagnosis of chronic idiopathic thrombocytopenia purpura (ITP)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q13. Does the patient have all of the following: A) inadequate response or inability to tolerate corticosteroids, B) duration of illness greater than six months, and C) platelet count persistently less than 20,000 per microliter? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q14. Does the patient have the diagnosis of chronic B-cell lymphocytic leukemia with immunoglobulin G (IgG) less than 600 mg/dL and recurrent, serious bacterial infections requiring antibiotic therapy? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q15. Does the patient have the diagnosis of hematopoietic stem cell transplant and immunoglobulin G (IgG) less than 400 mg/dL? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q16. Does the patient have the diagnosis of human immunodeficiency virus (HIV)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

| | |
|----------------------|-------------------------|
| Patient Name: | Prescriber Name: |
|----------------------|-------------------------|

| |
|--|
| <p>Q17. Does the patient meet all of the following: A) less than 14 years of age, B) evidence of qualitative or quantitative humoral immunologic defects and C) current bacterial infection despite antimicrobial prophylaxis? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q18. Has the member had a solid organ transplant? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q19. Does the patient have the diagnosis of chronic inflammatory demyelinating polyneuritis confirmed by electrodiagnostic testing or nerve biopsy and an inadequate response or inability to tolerate corticosteroids? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q20. Does the patient have the diagnosis of dermatomyositis or polymyositis diagnosed by laboratory testing (antinuclear or myositis specific antibodies, biopsy, electromyography [EMG], or magnetic resonance imaging [MRI]) AND inadequate response or inability to tolerate steroids or immunosuppressants? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q21. Does the patient have the diagnosis of Guillain-Barre syndrome with impaired function (i.e., unable to stand or walk without aid)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q22. Does the patient have the diagnosis of Lambert Eaton myasthenic syndrome (LEMS) refractory to steroids, immunosuppressants, or cholinesterase inhibitors? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q23. Does the patient have the diagnosis of multifocal motor neuropathy diagnosed by electrodiagnostic studies? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q24. Does the patient experience acute exacerbations of multiple sclerosis unresponsive to steroids? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q25. Does the patient have the diagnosis of myasthenia gravis that is refractory to at least 8 weeks of standard therapy (steroids, immunosuppressants, cholinesterase inhibitors)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |
| <p>Q26. Is the patient experiencing myasthenic crisis? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> |

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

| | |
|--|-------------------------|
| Patient Name: | Prescriber Name: |
| <p>Q27. Does the patient have the diagnosis of stiff person syndrome refractory to standard therapy (muscle relaxants, benzodiazepines, gabapentin)? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> | |
| <p>Q28. Does the patient have the diagnosis of severe, active systemic lupus erythematosus (SLE) unresponsive to steroids? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> | |
| <p>Q29. Does the patient have the diagnosis of Kawasaki disease? Must attach documentation.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p> | |
| <p>Q30. Additional Information:</p> | |
| <p>Q31. Duration:</p> <p><input type="checkbox"/> 3 months</p> | |

 Prescriber Signature

 Date

2022 Medicare Prior Authorization Request